Notable

THE FDA EXPANDED ITS APPROVAL OF IMFINZI®. The immunotherapy treatment is now available

as a standard-of-care option for patients with stage III non-small cell lung cancer. The expanded use

approval stems from a global clinical trial led by Moffitt thoracic oncologist Scott J. Antonia, MD, PhD.

MOFFITT MCKINLEY OUTPATIENT CENTER OPENED ITS SIXTH FLOOR ON MARCH 12.

The newly opened area houses the Senior Adult Oncology Program, GeneHome (a high-risk cancer screening

clinic), Survivorship Program, Breast Plastic Surgery, Genetic Risk Assessment, Cardio-Oncology,

Integrative Medicine-Massage Therapy and Multi-Specialty Clinic.

THE FDA APPROVED LUTATHERA® TO TREAT A RARE FORM OF CANCER. When injected into the

patient, the treatment delivers a high dose of targeted radiation to gastroenteropancreatic neuroendocrine

tumors. Moffitt oncologist Jonathan R. Strosberg, MD, led an international clinical trial leading to the

approval.